TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04357119

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One-anastomosis gastric bypass
Description: Laparoscopic single anastomosis gastric bypass is reported to be a safe alternative to LRYGB, showing comparable efficacy in weight reduction and resolution of metabolic complications with reduced surgical complications.~The advantages with this technique as claimed by those speaking in favor of it are many: fewer sites for leakage and internal hernia, easier and faster to learn and perform, easy to reverse and revise, and with results at least comparable with the result following standard Roux-en-Y gastric bypass (RYGB).~The length of the biliopancreatic limb in single anastomosis gastric bypass as reported by Rutledge is fixed 200 cm starting at the duodenojejunal junction, neglecting the length of the common limb.~Because of deficient data regarding the effect of common limb length on the outcome of LSAGB, so a clinical trial shall add new knowledge regarding sufficient weight loss, rate of complications and the need for revision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One-anastomosis gastric bypass
Description: Laparoscopic single anastomosis gastric bypass is reported to be a safe alternative to LRYGB, showing comparable efficacy in weight reduction and resolution of metabolic complications with reduced surgical complications.~The advantages with this technique as claimed by those speaking in favor of it are many: fewer sites for leakage and internal hernia, easier and faster to learn and perform, easy to reverse and revise, and with results at least comparable with the result following standard Roux-en-Y gastric bypass (RYGB).~The length of the biliopancreatic limb in single anastomosis gastric bypass as reported by Rutledge is fixed 200 cm starting at the duodenojejunal junction, neglecting the length of the common limb.~Because of deficient data regarding the effect of common limb length on the outcome of LSAGB, so a clinical trial shall add new knowledge regarding sufficient weight loss, rate of complications and the need for revision.
Study: NCT03988257

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Imunoglukan PH4
Description: Children allocated to experimental group will receive Imunoglukan PH4 syrup (10 mg of pleuran and 10 mg of vitamin C in 1 ml of syrup) in a dose 1 ml / 5 kg body weight, once a day in the morning, before the first meal, until signs of AGE subside (\< 3 stools / 24 hours and normalization of stool consistency - grade 2-5 according to Bristol Stool Form Scale) or until the 14th day of the intervention.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vitamin C syrup)
Description: Children allocated to control group will receive a placebo: a vitamin C syrup (10 mg of vitamin C in 1 ml of syrup) in a dose 1 ml / 5 kg body weight, once a day in the morning, before the first meal, until signs of AGE subside (\< 3 stools / 24 hours and normalization of stool consistency - grade 2-5 according to Bristol Stool Form Scale) or until the 14th day of the intervention.
Study: NCT01201798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluprednate 0.05% ophthalmic emulsion
Description: 1 drop in study eye, 4 times a day, for 14 days, followed by a 14-day tapering period dependent on the Investigator's determination of adequate response to treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone acetate 1.0% ophthalmic suspension
Description: 1 drop in study eye, 8 times a day, for 14 days, followed by a 14-day tapering period dependent on the Investigator's determination of adequate response to treatment
Study: NCT03147274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Patients randomized to the intervention group will attend 3 SMART T1D group curriculum sessions over the study period, in addition to usual diabetes clinic care. Each interactive group session will last 2 hours and will be facilitated by a diabetes nurse educator.
Study: NCT03880240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Alternating Current Stimulation (tACS)
Description: tACS is a non-invasive way of stimulating the brain externally using weak electric currents. Electrodes are placed into a cap that you wear on your head. A weak electrical current travels back and forth through the electrodes to your head. tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Alternating Current Stimulation (tACS)
Description: tACS is a non-invasive way of stimulating the brain externally using weak electric currents. Electrodes are placed into a cap that you wear on your head. A weak electrical current travels back and forth through the electrodes to your head. tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Alternating Current Stimulation (tACS)
Description: tACS is a non-invasive way of stimulating the brain externally using weak electric currents. Electrodes are placed into a cap that you wear on your head. A weak electrical current travels back and forth through the electrodes to your head. tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Alternating Current Stimulation
Description: Placebo Control, simulation of transcranial alternating current stimulation without receiving any stimulation
Study: NCT03949309

Intervention type: OTHER
Intervention: Exploring health literacy levels and patients' informal needs or individual relationship between caregivers and patients.
Description: It is a cross-sectional study coupled with a qualitative ancillary study conducted within patients hospitalized for one of the two acute cardiovascular diseases (acute coronary syndrome or acute heart failure). All patients hospitalized at Hospices Civils de Lyon for one of these two diseases and whom are going back home will be enrolled. Few patients will be interviewed during the follow-up visit at 1-month post hospitalisation. Caregivers from cardiology units will also be interviewed.
Study: NCT03473535

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BEACON + Problem Solving Therapy
Description: Six sessions of face-to-face PST delivered by a trained Research Therapist and access to the BEACON Suicide Prevention smartphone application.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem-Solving Therapy
Description: Six sessions of face-to-face PST delivered by a trained Research Therapist.
Study: NCT04396340

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XMT-1592
Description: XMT-1592 will be administered once every 21 or 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XMT-1592
Description: XMT-1592 will be administered once every 21 or 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.
Study: NCT01393119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-758
Description: 3-fluoro-N-( 4-fluorophenyl)-4-hydroxy-N-( 4-hydroxyphenyl) benzamide; a nonsteroidal selective estrogen receptor (ER) a agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-758
Description: 3-fluoro-N-( 4-fluorophenyl)-4-hydroxy-N-( 4-hydroxyphenyl) benzamide; a nonsteroidal selective estrogen receptor (ER) a agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-758
Description: 3-fluoro-N-( 4-fluorophenyl)-4-hydroxy-N-( 4-hydroxyphenyl) benzamide; a nonsteroidal selective estrogen receptor (ER) a agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-758
Description: 3-fluoro-N-( 4-fluorophenyl)-4-hydroxy-N-( 4-hydroxyphenyl) benzamide; a nonsteroidal selective estrogen receptor (ER) a agonist
Study: NCT03690778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-1310
Description: administration of JLP-1310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-1310
Description: administration of JLP-1310
Study: NCT00278161

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg SQ 24-48 hours after last dose of cyclophosphamide.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2/day on Days 1, 4, 8, 11, 45, and 52.
Study: NCT03758573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Description: Inspiratory Muscle Training (IMT)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Physiotherapy (IPT)
Description: Intensive Physiotherapy (IPT)
Study: NCT00278161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg/day on Days 15, 16, 17, and 18.
Study: NCT05168761

Intervention type: PROCEDURE
Intervention: partial nephrectomy
Study: NCT04556617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX2853
Description: PLX2853 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX2853
Description: PLX2853 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone acetate tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone (or equivalent) tablets
Study: NCT00950404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viagra 50 mg tablet
Description: Commercial tablet, 50 mg, single dose administered with water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B ODT tablet 50 mg
Description: Oral disintegrating tablet (ODT), 50 mg, single dose administered without water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation C ODT tablet 50 mg
Description: ODT, 50 mg, single dose administered without water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation D ODT tablet 50 mg
Description: ODT, 50 mg, single dose, administered without water
Study: NCT03646123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.2 mg/kg by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.2 mg/kg by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.2 mg/kg by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 25 mg/m\^2 by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 25 mg/m\^2 by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 25 mg/m\^2 by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine
Description: 6 mg/m\^2 by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: 375 mg/m\^2 by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: 375 mg/m\^2 by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: 375 mg/m\^2 by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Granulocyte colony stimulating factor (G-CSF) primary prophylaxis administered 24-36 hours after each dose of A+AVD
Study: NCT00651976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Take by mouth at a dose of 2.5 mg on days 7-21

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Collection
Description: Blood used for gene expression analysis and reverse transcriptase-polymerase chain reaction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy/lumpectomy/mastectomy
Description: Tissue collection,Surgery to remove tumor, Tumor tissues used for laboratory biomarker analysis
Study: NCT01881594

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure/Surgery
Description: daily stimulation of efferent loop prior to surgery (ileostomy closure)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure/Surgery
Description: daily stimulation of efferent loop prior to surgery (ileostomy closure)
Study: NCT04059445

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane)
Description: Regenerative therapy with biphasic calcium phosphate + collagen membrane.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane)
Description: Regenerative therapy with biphasic calcium phosphate + collagen membrane.
Study: NCT03646123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: 240 mg by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: 240 mg by IV infusion
Study: NCT00039455

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00918957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin Inhalation Powder
Description: Tobramycin Inhalation Powder as produced by a modified manufacturing process TIP. TIP was provided in hard capsules each containing 28 mg active ingredient (tobramycin); Capsules were packaged in blister cards and administered by the T-326 Inhaler.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhalation powder consisting of the excipients used for TIP. Placebo was provided in hard capsules, containing 20 mg placebo powder, which were packaged in blister cards, matching in appearance to TIP. Capsules were administered by the T-326 Inhaler.
Study: NCT06165185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Please see the associated arm description

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee
Description: Please see the associated arm description

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Please see the associated arm description
Study: NCT00938535

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Obesity Prevention
Description: This arm includes an action plan, tailored print materials, telephone support calls, interactive self-monitoring, and a 12-month YMCA membership for the participant.
Study: NCT01437358

Intervention type: OTHER
Intervention: Epidural analgesia
Description: The purpose of this observational prospective study is to describe the safety and feasibility of this analgesia technique in ICU patients
Study: NCT00793754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 100 mg / day for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 40 mg / day for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin + Atorvastatin
Description: Aspirin 100 mg / day + Atorvastatin 40 mg / day for 8 weeks
Study: NCT03804086

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advanced PRF (A-PRF) + nano-crystalline hydroxyapatite bone substitute combined with open flap debridement
Description: will treated with OFD +A- PRF+ nano-crystalline hydroxyapatite bone substitute,10 mL of blood will be drawn from only patient assigned to the intervention group by vein puncture of the antecubital vein and is collected in sterile glass test tube, without any anticoagulant.~* The blood will be quickly collected, and the tube will immediately centrifuge at 1500 rpm for14 min at room temperature.~* After centrifugation, the A-PRF clot will be removed from the tube using sterile tweezers and placed on sterile woven gauze. Membrane will prepared by compressing clots between two pieces of woven gauze.
Study: NCT04059445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)
Description: Regenerative therapy with biphasic calcium phosphate + enamel matrix proteins.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)
Description: Regenerative therapy with biphasic calcium phosphate + enamel matrix proteins.
Study: NCT02848300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 1% Formulation A
Description: Bimatoprost 1% Formulation A solution applied to the scalp and trunk once daily for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 1% Formulation B
Description: Bimatoprost 1% Formulation B solution applied to the scalp and trunk once daily for 14 days.
Study: NCT01208038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrinsa Transdermal testosterone patch
Description: 300 microgram transdermal testosterone patch, applied twice weekly for 12 weeks
Study: NCT01769079

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate
Description: Two arms: placebo and nitrate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02218658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WE941 OD tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brotizolam
Study: NCT02499003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab and Pixantrone
Description: Obinutuzumab: 1000 mg flat dose on day 1, 8, 15 of cycle one and day 1 of subsequent cycles, Pixantrone: 50 mg/m² Pixantrone on day 1,8,15 of each 28 d cycle
Study: NCT03086200

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief Motivational Interviewing
Description: All study participants will receive daily dosing text message reminders.~Participants randomized to the MI-b Intervention and who are persistently non-adherence based on negative or non-responses to iTAB will be sent automated high alert messages notifying the participant to take their study medication and respond to iTAB. Both the study coordinator and the MI counselor will also receive the high alert message. Participants will be contacted by the MI counselor for a phone MI-b session within 72 hours of a high alert message to discuss adherence. Participants who continue to be non-adherent despite receiving these messages will be switched to receive alert messages on a monthly schedule.
Study: NCT03804086

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement
Description: a periodontal access flap will be initiated by intrasulcular incisions on the buccal and lingual aspects. The incisions will be carried as far interproximally as possible to preserve the entire Interdental papillae and to achieve primary wound closure.
Study: NCT00332644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine patch
Description: used according to FDA package label
Study: NCT03350945

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Device: tumor localization
Description: At present, three dominant methods can be available to locate tumor: preoperative endoscopic clip placement, intraoperative endoscopy and endoscopic tattooing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Device: tumor localization
Description: At present, three dominant methods can be available to locate tumor: preoperative endoscopic clip placement, intraoperative endoscopy and endoscopic tattooing
Study: NCT00332644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine lozenge
Description: used according to FDA-approved package directions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine patch + nicotine lozenge
Description: dosage of both according to FDA-approved dosing schedule
Study: NCT03350945

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Device: tumor localization
Description: At present, three dominant methods can be available to locate tumor: preoperative endoscopic clip placement, intraoperative endoscopy and endoscopic tattooing
Study: NCT00878657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Pre-Chemoradiation (Induction) Chemotherapy Gemcitabine will be given weekly for seven doses at a dose of 1000 mg/m2/wk (Days 1, 8, 15, 22, 29, 36, 43) unless toxicity develops. Chemoradiation gemcitabine will be given 400 mg/m2, infused over 30 minutes, within 120 minutes before radiotherapy. Post-chemoradiation chemotherapy, patients will receive two cycles of gemcitabine. A cycle will be defined as three weeks of gemcitabine at 1000 mg/m2/d, once weekly, followed by a one-week rest.
Study: NCT04768244

Intervention type: OTHER
Intervention: maternal SARS-CoV-2 infection
Description: positive PCR in nasopharinx and/or presence of antibodies in serum
Study: NCT02150746

Intervention type: PROCEDURE
Intervention: Peripheral/Central Venous Blood Draw
Description: Baseline sample of whole blood to be assessed for circulating tumor cells. Samples will be acquired via venipuncture unless a pre-existing central venous catheter is in place in which case the sample will be drawn from this.

Intervention type: PROCEDURE
Intervention: Peritoneal Wash
Description: Prior to the start of the surgical resection, irrigation of the abdominal cavity will be performed and collected to determine baseline pancreatic cancer cells that may be present in the abdominal cavity.